Hagens Berman & Paragon Therapeutics
2 shared events · Importance 3 · Last updated Sep 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Hagens Berman: Filed a class action lawsuit against Capricor.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
Regulatory
Hagens Berman: The firm notified investors of the September 28, 2026 deadline and highlighted the FDA's extension of the BLA review period.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
90
Hagens Berman filed class action Paragon TherapeuticsCapricor Deramiocel...
87
Hagens Berman filed class action lawsuit Paragon TherapeuticsCapricor Deramiocel...
70
Hagens Berman filed securities class action Paragon TherapeuticsCapricor Deramiocel...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Hagens Berman and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard